Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 27

Total 27 documents found.

  •  
  • Building Toward Leadership in Oncology Deborah Dunsire, MD President and Chief Executive Officer, Millennium: The Takeda Oncology Company Disclaimer This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All f d l ki t t t b d j d t d i d f th i f ti il bl t thAll forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward-looking statements can sometimes be identified by the use of forwardlooking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target," "forecast," "intend" or other similar words or expressions of the negative thereof. Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward-looking statements contained in this presentation. These risks and uncertainties include, but are not limited to: (1) the
  • FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000099 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market
  • ANNUALREPORT2009TakedaPharmaceuticalCompanyLimited Annual Report 2009 Our Contribution to Financial and Social Responsibility Editorial Policy Takeda integrates its annual report and CSR report into a single publication with a mind to give readers a complete understanding of how our business operations are guided by Takeda-ism and other elements of our corporate philosophy. Contributes to the Health of Individuals Takeda has been supplying pharmaceuticals for more than 220 years while never forgetting the importance of protecting and preserving life. Over the years, we have developed a strong commitment to the highest ethical standards and strong sense of mission. As our operations became global in scale, demands concerning corporate social responsibility (CSR) increased. We believe that developing superior pharmaceutical products in accordance with the principles of Takeda-ism is the essence of CSR for the Takeda Group. Due to this strong link between our business activities and CSR, since fiscal 2006, Take
  • 36 Enhancement of the R&D Pipeline through In-Licensing and Alliance Activities R&D Alliance Note: Established in 2002, Teijin Pharma Limited is the core company of Teijin Group's medical and pharmaceuticals business. Its main businesses are in pharmaceuticals and delivery of home healthcare services. It specializes in the development of innovative products and services in the three fields of bone and joint diseases. respiratory disease, and metabolic and cardiovascular disease. Partner's Voice Takeda is a Japanese company that has enjoyed considerable international success. In 1999, we entered into a licensing agreement with Takeda's U.S. subsidiary TPNA for ULORIC (generic name: febuxostat), a treatment for hyperuricemia in patients with gout. I have since been deeply impressed with Takeda's superb development capabilities and their attitude in constantly rising to the challenge of overcoming numerous obstacles. All these efforts have now paid off, and I am delighted that the product was launched in the U.
  • SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Financial Results for the First Three Quarters (April 1 to December 31, 2009) of the Fiscal Year Ending March 31, 2010 February 3, 2010 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hiroshi Ohtsuki Corporate Officer, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 15, 2010 Scheduled date of dividend payment commencement: 1. Consolidated Financial Results (April 1 to December 31, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( milli
  • X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Recent progress in stage ■ Discontinued project ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities - 17 - Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license MEPACT Immunostimulant (injection) Non-metastatic osteosarcoma EU Approved (Mar 09) In-house SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) Diabetes mellitus (Concomitant therapy with thiazolidinediones) Diabetes mellitus (Fixed-dose combination with metformin) US Jpn EU US Jpn EU Jpn - FDA Complete Response Letter (Jun 09) Filed (Sep 08) P-III FDA Complete Response Letter (Sep 09) Filed (Jun 09) P-III Filed (Jun 09) P-I In-house TAK-375 MT1/MT2 receptor agoni
  • Date Summary 9-Apr-09 Nature Publishes Pre-clinical Data on an Inhibitor of a Novel Target Discovered by Millennium 23-Apr-09 Lancet Publishes Phase 3 Clinical Data on Basen 7-May-09 Takeda to integrate its two manufacturing operations in Ireland 7-May-09 Takeda to Start Sales and Marketing Operation in Portugal 14-May-09 FDA Approves ACTOplus met XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes First and only oral antidiabetic fixed-dose combination medication approved with the extended-release form of metformin 18-May-09 Takeda to Acquire IDM Pharma, Adding Mepact (Mifamurtide), The First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 26-May-09 Takeda to License Vaccine for Haemophilus Influenzae Type B from Novartis 4-Jun-09 Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filing in Europe 8-Jun-09 Update on Lu AA21004 clinical development programme in major depressive disorder (MDD) 18-Jun-09 New Dosa
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Three Months Results (April 1 to June 30, 2009) for the Fiscal Year Ending March 31, 2010 July 31, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: August 11, 2009 1. Consolidated Financial Results (April 1 to June 30, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Three months ended June 30, 2009 378,977 (4.5) 125,630 137,594 112,594 Three months e
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Financial Results for the First Two Quarters (April 1 to September 30, 2009) of the Fiscal Year Ending March 31, 2010 October 30, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hiroshi Ohtsuki Corporate Officer, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: November 13, 2009 Scheduled date of dividend payment commencement: December 1,2009 1. Consolidated Financial Results (April 1 to September 30, 2009) of the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( millio
  • Takeda to License Vaccine for Haemophilus Influenzae Type B from Novartis May 26, 2009
  • May 26, 2009, Osaka, Japan --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it entered into agreement with Novartis (Switzerland, “Novartis”) for vaccine for prevention of infection caused by Haemophilus Influenzae Type B (“Hib”). Novartis has developed that vaccine, known as “Vaxem Hib®”, by combining it with detoxified diphtheria toxin in order to increase immunogenicity, assuring the potential to induce the production of antibody in infants.
  • Takeda to Create Global Centers of Excellence
    Reorganization helps Takeda realize globalization vision March 31, 2009
  • Osaka, Japan, March 31, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.
  • Appointment of New CEO of Takeda Pharmaceuticals Asia Private Limited January 13, 2009
  • Osaka, Japan, January 13, 2009 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced the appointment of Mr. Stefan Ziegler as CEO of Takeda Pharmaceuticals Asia Private Limited (“TPAsia”), its wholly owned subsidiary for oversight of overall Asian sales and marketing. Mr. Ziegler received a bachelor’s degree in Business administration with major in Finance and Marketing at University of Zurich in Switzerland and worked at Novartis from 1990 to 2008.
  • Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics May 27, 2008
  • CAMBRIDGE, Mass., USA and OSAKA, Japan, May 27, 2008 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas. This landmark alliance is the first major RNAi therapeutics partnership between a Japanese pharmaceutical company and a U.S. biotechnology company, representing a new frontier in the advancement of RNAi therapeutics to patients on a global basis.
  • European EMEA acceptance of Marketing Authorization Application filing for SNT-MC17 in Friedreich’s Ataxia by Santhera August 17, 2007
  • Liestal, Switzerland and Osaka, Japan, August 16, 2007 – Santhera Pharmaceuticals (SWX: SANN, “Santhera”), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, and Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”), jointly announced today that the European Medicines Agency (EMEA) has accepted the filing of Marketing Authorization Application (MAA) for Santhera’s lead compound SNT-MC17 (INN: idebenone, originally developed by Takeda) for the treatment of Friedreich’s Ataxia (FRDA). SNT-MC17, which has been granted orphan drug designation in the EU, could become the first approved product for the treatment of FRDA and will be marketed in Europe by Santhera’s partner Takeda. SNT-MC17 has shown clinical efficacy in FRDA patients on neurological as well as cardiac endpoints in several clinical studies and proved to be well tolerated in all studies so far.
  • XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development February 28, 2007
  • Berkeley, CA, and Osaka, JAPAN - February 28, 2007 - XOMA Ltd. (Nasdaq: XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have amended their existing agreement to increase the number of potential therapeutic antibody programs under the collaboration initiated in November of 2006.With this expansion, XOMA estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million before royalties over the life of the agreement. Since entering the original agreement four months ago, XOMA has receivedor is otherwise due approximately $8 million as various collaboration-related payments.
  • CEO of a New Company for European Operations Appointed December 5, 2006
  • Osaka, Japan, December 5, 2006 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that, on December 1, Mr. Giacomo Di Nepi joined Takeda as CEO of the new company for Takeda European Operations, Takeda Pharmaceuticals Europe Limited ("TPEU"), which was established as a wholly owned subsidiary in last August and is now starting its activities.

Pages:[1] [2]   Next

Page Top